Prognostic significance of presence of RD in patients in morphologic CR by univariate Cox analyses
| . | OS from end of induction 1 . | RFS from end of induction 1 . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR 95% CI . | P . | |
| Univariate Cox analyses | ||||
| RD at end of induction 1 | ||||
| Negative | 1 | 1 | ||
| Positive | 2.46 (1.35-4.47) | .003 | 2.46 (1.52-3.97) | < .001 |
| Molecular risk group | ||||
| Standard | 1 | 1 | ||
| Favorable (CBF, NPM1, CEBPA) | 0.52 (0.25-1.09) | .083 | 0.83 (0.49-1.40) | .484 |
| Unfavorable (−7, −5/del(5q), FLT3-ITD high AR) | 3.36 (1.50-7.55) | .003 | 2.72 (1.30-5.68) | .008 |
| WBC count at study entry | ||||
| < 100 000/μL | 1 | 1 | ||
| ≥ 100 000/μL | 0.56 (0.22-1.41) | .215 | 0.79 (0.42-1.50) | .470 |
| Multivariate cox analyses | ||||
| RD at end of induction I | ||||
| Negative | 1 | 1 | ||
| Positive | 1.87 (0.97-3.58) | .060 | 2.38 (1.43-3.97) | < .001 |
| Molecular risk group | ||||
| Standard | 1 | 1 | ||
| Favorable (CBF, NPM1, CEBPA) | 0.59 (0.28-1.25) | .167 | 0.75 (0.55-1.62) | .841 |
| Unfavorable (−7, −5/del(5q), FLT3-ITD high AR) | 3.20 (1.42-7.21) | .005 | 2.84 (1.35-5.97) | .006 |
| WBC count at study entry | ||||
| < 100 000/μL | 1 | 1 | ||
| ≥ 100 000/μL | 0.71 (0.28-1.82) | .476 | 0.93 (0.49-1.79) | .837 |
| . | OS from end of induction 1 . | RFS from end of induction 1 . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR 95% CI . | P . | |
| Univariate Cox analyses | ||||
| RD at end of induction 1 | ||||
| Negative | 1 | 1 | ||
| Positive | 2.46 (1.35-4.47) | .003 | 2.46 (1.52-3.97) | < .001 |
| Molecular risk group | ||||
| Standard | 1 | 1 | ||
| Favorable (CBF, NPM1, CEBPA) | 0.52 (0.25-1.09) | .083 | 0.83 (0.49-1.40) | .484 |
| Unfavorable (−7, −5/del(5q), FLT3-ITD high AR) | 3.36 (1.50-7.55) | .003 | 2.72 (1.30-5.68) | .008 |
| WBC count at study entry | ||||
| < 100 000/μL | 1 | 1 | ||
| ≥ 100 000/μL | 0.56 (0.22-1.41) | .215 | 0.79 (0.42-1.50) | .470 |
| Multivariate cox analyses | ||||
| RD at end of induction I | ||||
| Negative | 1 | 1 | ||
| Positive | 1.87 (0.97-3.58) | .060 | 2.38 (1.43-3.97) | < .001 |
| Molecular risk group | ||||
| Standard | 1 | 1 | ||
| Favorable (CBF, NPM1, CEBPA) | 0.59 (0.28-1.25) | .167 | 0.75 (0.55-1.62) | .841 |
| Unfavorable (−7, −5/del(5q), FLT3-ITD high AR) | 3.20 (1.42-7.21) | .005 | 2.84 (1.35-5.97) | .006 |
| WBC count at study entry | ||||
| < 100 000/μL | 1 | 1 | ||
| ≥ 100 000/μL | 0.71 (0.28-1.82) | .476 | 0.93 (0.49-1.79) | .837 |
RD indicates residual disease; CR, complete remission; OS, overall survival; RFS, relapse-free survival; HR, hazards ratio; CI, confidence interval; ITD, internal tandem duplication; AR, absolute risk; and WBC, white blood cell.